Mentari raises additional $200M private placement; extends cash runway into 2029

InMed Pharmaceuticals Inc.

Additional $200M private placement from Fairmount, ADAR1, Venrock, Blackstone, Janus Henderson, and other healthcare investors.
Proceeds extend cash runway into 2029 and through Phase 2a readout for PACAP-targeted programs including MT-002.
Post-merger, pre-Merger Mentari stockholders own ~98.85% of combined company; InMed shareholders ~1.15%; total shares ~601M.
Private placement expected to close immediately prior to merger completion, concurrent with previously announced $290M placement.
Combined company to operate as Mentari Therapeutics and trade on Nasdaq under a new ticker symbol.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.